xl999

XL999 is a small molecule multi-targeted tyrosine kinase inhibitor developed as an investigational anticancer agent. It inhibits several receptor tyrosine kinases (RTKs) involved in tumor growth and angiogenesis, including fibroblast growth factor receptors 1 and 3 (FGFR1/3), vascular endothelial growth factor receptor 2 (VEGFR2/KDR), platelet-derived growth factor receptors alpha and beta (PDGFRα/β), KIT, FMS-like tyrosine kinase 3 (FLT3), FLT4, RET, and SRC. By blocking these kinases, XL999 disrupts both tumor cell proliferation directly and the formation of new blood vessels that supply tumors. Preclinical studies demonstrated broad antitumor activity in xenograft models. Clinical development reached phase II for some indications but was discontinued for all known cancer types[1][2][5][8].

Other names

Tyrosine kinase-IN-1705946-27-66I7PLF6N8L